In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.

September 26, 2024 – ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, ...

The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached ...

BioBridges has been a trusted partner in the life sciences industry for more than 20 years. With the launch of its new ...

Solventum, formerly 3M Health Care, announced today the launch of the 3M™ Harvest RC Centrate Chromatographic Clarifier, a ...

The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.

The financing will support a technology designed to make delivery of lentiviral gene therapies, which are typically administered through a complex process, more convenient.

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.